Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GMA-161
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GMA-161 is a humanized, aglycosyl monoclonal antibody that targets the human low-affinity Fc gamma receptor III (CD16), also known as FcγRIII. It was developed for the treatment of autoimmune disorders, specifically idiopathic thrombocytopenic purpura (ITP). The drug acts as an antagonist of CD16 and was designed to block the deleterious action of self-directed antibodies mediated by this receptor. Preclinical studies were conducted in transgenic mice expressing both isoforms of human CD16 (CD16A and CD16B), which supported its transition into phase I clinical trials. However, development was discontinued after early-phase clinical evaluation due to adverse reactions observed in preclinical models. The drug was originally developed by Genzyme Corporation and MacroGenics; later development efforts involved Sanofi following acquisition[5][6][7][8].
- Other names
- HUMANIZED, AGLYCOSYL ANTIBODY, GMA161
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGR3B (Low affinity immunoglobulin gamma Fc region receptor III-B)
Beyond the preview
Go deeper on GMA-161.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GMA-161.